Genedata, the leading provider of in-silico solutions for pharmaceutical R&D and related life sciences, today announced the release of Genedata Screener® 6.0, the latest version of its open and scalable enterprise solution for high throughput screening (HTS) and high content screening (HCS) analysis. Screener 6.0 combines an enterprise-wide assay data management platform with high-performance processing workflows and flexible analysis tools and has a special focus on time series data analysis.
Time series data is complex with hundreds of values per well. Sensible data aggregation is needed to derive meaningful results from such time-dependent responses. The latest Screener release includes an enhanced solution to these kinetics assay data management challenges. This new functionality enables users to rapidly analyze, integrate and manage extensive sets of time series data, independent of instrumentation, technology, volume or location.
In the Kinetics Assay module users can optimize aggregation rules, re-analyze data for complete campaigns and systematically gather mechanistic information from curve shape in addition to amplitude. The application programming interfaces (APIs) included in this open system can be easily connected to the many different readers already on the market, as well as implemented to provide custom aggregation functions for specific experiments. Quality assessment and visualization are vastly improved and interferences with biological response can be identified from kinetics traces. With consistent data management and visualization, the resulting parameters are optimized for each assay and users are able to extract more information to get better results and better qualified hits from each single experiment.
“Genedata Screener is already licensed by the top pharmaceutical, agrochemical and life science biotech companies worldwide,” said Dr. Othmar Pfannes, CEO of Genedata. “With the addition of the Kinetics Analyzer module, Screener 6.0 extends the use of our enterprise high throughput and high content screening platform to the rapidly growing market of time series data analysis. More than ever before research groups spanning the globe can easily analyze, manage and share complex data regardless of the instrumentation they use.”
Genedata (genedata.com) develops and globally markets sophisticated computational solutions for drug discovery and related research processes in the life sciences. Genedata’s solutions enable scientists to process, integrate, analyze, and manage large and complex experimental data sets generated by high-throughput technologies. Our solutions include Genedata Phylosopher® for target discovery and integrative biological data management, Genedata Screener® for automated high throughput screening and high content screening, and Genedata Expressionist® for biomarker discovery and personalized medicine. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Boston & San Francisco, USA, Konstanz & Munich, Germany and Tokyo, Japan.